Module 7: Additional Resources

COVID-19 Vaccination after mAb Administration

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the US

• Non-hospitalized COVID-19 patients who previously received passive antibody therapy
  • There is no longer any need to delay vaccination following receipt of monoclonal antibody or convalescent plasma beyond recovery from the acute illness (if symptoms were present) and criteria to discontinue isolation have been met.
• Hospitalized COVID-19 patients
  • Follow guidelines from CDC Advisory Committee on Immunization Practices

For USG Procurement Reporting Guidance

For sotrovimab, bam/ete, REGEN-COV, bebtelovimab, Evusheld

Reporting required once a month by 11:59 pm ET on the last day of the month

For Paxlovid
and
Lagevrio

Reporting required at least twice a month by 11:59 pm ET on the 15th and last day of the month

• Reporting stock on hand is the minimal requirement if a therapeutic has not been administered, transferred, or wasted within the reporting period
• Please ensure accurate reporting, including when there is a significant change to stock on hand, e.g., if a specific lot of therapeutics expires and is wasted

Sites with inventory of USG-purchased COVID-19 therapeutics must provide information on product utilization, wastage, returns, and stock on hand.

Opting in to the Treatments Locator

• USG has developed a mechanism for providers to report commercial treatment locations voluntarily that will be visible in an expanded treatments locator tool.
  • As of November 27, sites could voluntarily upload commercially acquired inventory data for Paxlovid, Lagevrio, and outpatient Veklury via HPOP.
  • HPOP users can leverage their existing accounts to report, while non-HPOP users can report using the HPOP volunteer reporting website.
  • If a site opts in, that site will become publicly visible on the Treatments Locator.
  • We encourage sites to report commercial therapeutics as often as possible; reporting commercially distributed therapeutics at least every 14 days is requested to ensure the locator remains accurate.
  • After 60 days, sites will fall off the locator until commercial inventory is reported again.
  • Separately, USG-distributed product should continue to be entered in the appropriate HPOP reporting fields.

Learn more in the COVID-19 Therapeutics Transition Guide

Voluntary Reporting of Commercial Therapeutics

• HPOP users can use HPOP for voluntary reporting.
• Non-HPOP users can use the HPOP Volunteer Reporting website to voluntarily report availability of commercial therapeutics.

COVID-19 Therapeutic Resources

• Administration for Strategic Preparedness and Response
• For the latest information on all COVID-19 therapeutics, refer to:
  • FDA’s COVID-19 EUA Information
  • ASPR's COVID-19 Therapeutics Resources
• Still have questions? Reach out to HHS COVID 19 Therapeutics email